Prevention: Vaccine Development
Comprehensive strategies to control and eventually eliminate TB involve many interconnected components, including developing new vaccines. NIAID is providing support to help identify new candidate TB vaccines and immune-boosting vaccine adjuvants to prevent infection or disease and is evaluating the potential of synthetic vaccines to help shorten TB drug treatment regimens.
In addition, NIAID funds vaccine development, including preclinical animal studies and clinical research on those candidate TB vaccines that appear most promising. Several candidates that demonstrated protection against infection with Mycobacterium tuberculosis in small animal models have entered human clinical trials.
Research Feature Stories